

By Gabe Whisnant
News Editor
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
Federal regulators on Wednesday approved Eli Lilly’s new weight‑loss pill, making it the second once‑daily oral medication authorized to treat obesity and related weight‑associated conditions in the United States. The approval marks a new option for patients seeking alternatives to injectable GLP‑1 drugs.
The Food and Drug Administration (FDA) granted expedited approval to orforglipron, a GLP‑1 drug that works similarly to widely used injectable treatments by mimicking a natural hormone that helps regulate appetite and feelings of fullness.
What Is Orforglipron and How Does It Work?
The medication will be sold under the brand name Foundayo and is designed as a small‑molecule GLP‑1 drug, allowing it to be taken as a pill without dietary restrictions. That distinguishes it from peptide‑based oral GLP‑1 medications, which require specific timing and fasting conditions.
Read More on U.S.
GLP‑1 drugs have become increasingly popular for weight loss and diabetes treatment by signaling the brain to reduce hunger and slowing digestion.
The approval could expand access to weight‑loss treatment for millions of Americans who have been unable or unwilling to use injectable drugs because of cost, needle aversion or strict dosing requirements. As a once‑daily pill, orforglipron may be easier for patients to take consistently, and Eli Lilly’s lower pricing—particularly for insured patients—could make treatment more affordable.
Public health experts say broader access to oral GLP‑1 medications could significantly increase the number of people able to seek medical treatment for obesity, a condition that affects more than 40 percent of U.S. adults.

...
When Will the Drug Be Available and How Much Will It Cost?
Eli Lilly said shipments of Foundayo are expected to begin Monday. With the company’s discount card, insured patients may be able to access the drug starting at $25 per month.
For patients paying cash, monthly prices will range from $149 to $349, depending on the dose, according to the company.
How Effective Is the Weight-Loss Pill?
In a clinical trial involving more than 3,000 adults with obesity, participants who received the highest dose of orforglipron—36 milligrams—lost an average of 11.2 percent of their body weight, or about 25 pounds, over more than 16 months.
That compared with an average weight loss of 2.1 percent, or less than 5 pounds, among patients who received a placebo, according to results published in the New England Journal of Medicine. Participants taking the drug also saw improvements in waist circumference, blood pressure, triglycerides and cholesterol levels.
How Does It Compare With Other GLP-1 Drugs?
Orforglipron joins Novo Nordisk’s oral version of Wegovy, which has generated more than 600,000 prescriptions in the United States since its approval in December.
While the daily pills offer greater convenience, both produced less weight loss than injectable GLP‑1 treatments. Lilly’s injectable Zepbound results in an average weight loss of about 21 percent, while Wegovy averages about 15 percent.
Unlike Novo Nordisk’s oral pill, which must be taken with a sip of water on an empty stomach followed by a 30‑minute wait before eating or drinking, orforglipron can be taken without such restrictions.
Safety, Side Effects and FDA Review
Gastrointestinal side effects led between 5 percent and 10 percent of participants taking orforglipron to discontinue treatment, compared with nearly 3 percent of those in the placebo group.
The FDA approved the drug through a new fast‑track review program aimed at shortening approval timelines, saying it reviewed Lilly’s application in just 50 days.
About one in eight people in the U.S. have used injectable GLP‑1 drugs, according to KFF, but high costs have limited access for many patients. Lilly said its new pill will be included in a Trump administration deal aimed at lowering prices on GLP‑1 medications.
This article includes reporting by the Associated Press.
Update 4/1/26, 4:16 p.m. ET: This article was updated with new information.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines